JP2023537115A5 - - Google Patents
Info
- Publication number
- JP2023537115A5 JP2023537115A5 JP2023509614A JP2023509614A JP2023537115A5 JP 2023537115 A5 JP2023537115 A5 JP 2023537115A5 JP 2023509614 A JP2023509614 A JP 2023509614A JP 2023509614 A JP2023509614 A JP 2023509614A JP 2023537115 A5 JP2023537115 A5 JP 2023537115A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- binds
- human
- protein
- weeks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063065085P | 2020-08-13 | 2020-08-13 | |
| US63/065,085 | 2020-08-13 | ||
| PCT/EP2021/072020 WO2022033978A2 (en) | 2020-08-13 | 2021-08-06 | Cancer treatment methods using anti-cd73 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023537115A JP2023537115A (ja) | 2023-08-30 |
| JP2023537115A5 true JP2023537115A5 (enExample) | 2024-08-08 |
Family
ID=77595505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023509614A Ceased JP2023537115A (ja) | 2020-08-13 | 2021-08-06 | 抗ｃｄ７３抗体を使用する癌処置方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240270865A1 (enExample) |
| EP (1) | EP4196500A2 (enExample) |
| JP (1) | JP2023537115A (enExample) |
| KR (1) | KR20230050378A (enExample) |
| CN (1) | CN116194483A (enExample) |
| WO (1) | WO2022033978A2 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220002959A (ko) | 2019-04-23 | 2022-01-07 | 이나뜨 파르마 에스.에이. | Cd73 차단 항체 |
| WO2025162964A1 (en) | 2024-01-30 | 2025-08-07 | Institut National de la Santé et de la Recherche Médicale | Methods for the treatment of endometriosis |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| WO2003087339A2 (en) | 2002-04-11 | 2003-10-23 | Medimmune Vaccines, Inc. | Spray freeze dry of compositions for pulmonary administration |
| EP1494651A4 (en) | 2002-04-11 | 2010-10-13 | Medimmune Vaccines Inc | PRESERVATION OF BIOACTIVE MATERIALS WITH FREEZZED FOAM |
| US20040042972A1 (en) | 2002-04-11 | 2004-03-04 | Medimmune Vaccines, Inc. | Spray freeze dry of compositions for intranasal administration |
| JP2006512102A (ja) | 2002-04-11 | 2006-04-13 | メディミューン・ヴァクシンズ・インコーポレーテッド | 噴霧乾燥による生物活性材料の防腐 |
| CA2487932A1 (en) | 2002-05-30 | 2003-12-11 | Macrogenics, Inc. | Cd16a binding proteins and use for the treatment of immune disorders |
| KR20050088175A (ko) | 2002-12-17 | 2005-09-02 | 메드이뮨 백신즈 인코포레이티드 | 생물활성 물질의 고압 분무 건조 |
| CN102711810B (zh) | 2009-11-30 | 2015-04-22 | 詹森生物科技公司 | 效应子功能已消除的抗体Fc区突变体 |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| US10195288B2 (en) | 2012-10-11 | 2019-02-05 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate |
| AP2016009222A0 (en) * | 2013-11-04 | 2016-05-31 | Glenmark Pharmaceuticals Sa | Production of t cell retargeting hetero-dimeric immunoglobulins |
| WO2015164723A1 (en) * | 2014-04-25 | 2015-10-29 | The Trustees Of The University Of Pennsylvania | Methods and compositions for treating metastatic breast cancer and other cancers in the brain |
| WO2016055609A1 (en) * | 2014-10-10 | 2016-04-14 | Innate Pharma | Cd73 blockade |
| US20180030144A1 (en) * | 2014-10-10 | 2018-02-01 | Innate Pharma | Cd73 blockade |
| EP3259288B1 (en) | 2015-02-20 | 2026-07-22 | Innate Pharma | Cd73 blockade |
| CA3045376C (en) | 2017-01-24 | 2022-08-30 | I-Mab | Anti-cd73 antibodies and uses thereof |
| MX2019015885A (es) | 2017-06-22 | 2020-09-10 | Novartis Ag | Moleculas de anticuerpo que se unen a cd73 y usos de las mismas. |
| US20200172628A1 (en) * | 2017-06-22 | 2020-06-04 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| SG11202001514XA (en) | 2017-08-31 | 2020-03-30 | Daiichi Sankyo Co Ltd | Novel method for producing antibody-drug conjugate |
| CN119431579A (zh) * | 2018-03-09 | 2025-02-14 | 艾吉纳斯公司 | 抗cd73抗体及其使用方法 |
| TWI870353B (zh) * | 2018-06-18 | 2025-01-21 | 法商天賜製藥公司 | 用於治療癌症之組合物及方法 |
| WO2020041404A1 (en) * | 2018-08-23 | 2020-02-27 | Macrogenics, Inc. | Pd-l1-binding molecules and use of the same for the treatment of disease |
| KR20220002959A (ko) * | 2019-04-23 | 2022-01-07 | 이나뜨 파르마 에스.에이. | Cd73 차단 항체 |
-
2021
- 2021-08-06 KR KR1020237007954A patent/KR20230050378A/ko not_active Withdrawn
- 2021-08-06 EP EP21763253.8A patent/EP4196500A2/en active Pending
- 2021-08-06 US US18/020,955 patent/US20240270865A1/en active Pending
- 2021-08-06 CN CN202180055645.3A patent/CN116194483A/zh active Pending
- 2021-08-06 JP JP2023509614A patent/JP2023537115A/ja not_active Ceased
- 2021-08-06 WO PCT/EP2021/072020 patent/WO2022033978A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9522956B2 (en) | Combination therapy using anti-EGFR and anti-HER2 antibodies | |
| CN101970499B (zh) | 用于肿瘤治疗的单克隆抗体 | |
| CA2436326C (en) | Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors | |
| AU2019202283A1 (en) | Trispecific binding proteins and methods of use | |
| JPH08504172A (ja) | 抗−ｅｒｂＢ−２モノクロナール抗体の組み合わせ物及び使用方法 | |
| JP2004501101A (ja) | Ｈｅｒ２に対する抗体およびインターロイキン−２の組み合わせの使用による癌の処置 | |
| US20120294873A1 (en) | ANTI-EpCAM IMMUNOGLOBULINS | |
| EP1282440A1 (en) | Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumor agents | |
| WO2023061472A1 (zh) | 抗her2抗体药物偶联物和酪氨酸激酶抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2023544143A5 (enExample) | ||
| JP2022513421A5 (enExample) | ||
| JP2022541591A5 (enExample) | ||
| WO2025103379A1 (zh) | 抗b7h3抗体-药物偶联物治疗癌症的方法 | |
| JPS63238023A (ja) | 抗腫瘍イムノトキシン及び腫瘍壊死因子を含んで成る医薬 | |
| CN118373896B (zh) | 抗pd-1抗体与il-2突变体的双功能融合蛋白 | |
| JP2022502434A5 (enExample) | ||
| KR101746152B1 (ko) | ＥｒｂＢ3에 특이적으로 결합하는 항체 및 그의 용도 | |
| JP2023545983A5 (enExample) | ||
| JP2005525317A (ja) | Ｈｅｒ２レセプタータンパク質の過剰発現によって特徴づけられる癌のための組み合わせｉｌ−２／抗ｈｅｒ２抗体治療 | |
| CN121622921A (zh) | Her2 adc药物组合物及其用途 | |
| WO2025252203A1 (zh) | 抗Nectin-4抗体药物偶联物治疗肿瘤的用途 | |
| WO2025201522A1 (zh) | 抗Nectin-4抗体药物偶联物治疗肿瘤 | |
| CN113993544A (zh) | 用于治疗egfr高表达的癌症的多变剂量方法 | |
| JPH06509541A (ja) | 免疫複合体 | |
| WO2003057250A1 (en) | Cancer treatment |